Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Prescription-event monitoring and reporting of adverse drug reactions.

Heeley E, Riley J, Layton D, Wilton LV, Shakir SA.

Lancet. 2001 Dec 1;358(9296):1872-3.

PMID:
11741629
2.
3.

The way towards adverse event monitoring in clinical trials.

Wallander MA.

Drug Saf. 1993 Mar;8(3):251-62. Review.

PMID:
8452665
4.

[Pharmacovigiance: The spontaneous reporting system in Switzerland].

Schäublin M.

Ther Umsch. 2015 Dec;72(11-12):743-8. doi: 10.1024/0040-5930/a000746. Review. German.

PMID:
26654819
5.

Safety monitoring of new anti-malarials in immediate post-marketing phase.

Edwards IR.

Med Trop (Mars). 1998;58(3 Suppl):93-6. Review.

PMID:
10212911
6.

Modern methods of pharmacovigilance: detecting adverse effects of drugs.

Norén GN, Edwards IR.

Clin Med (Lond). 2009 Oct;9(5):486-9. Review. No abstract available.

PMID:
19886114
7.
8.

[Safety of medicinal products and reporting of adverse drug reactions].

Skibicka I, Maciejczyk A.

Neurol Neurochir Pol. 2004 Nov-Dec;38(6):503-10. Review. Polish.

PMID:
15654675
9.

Limitations and strengths of spontaneous reports data.

Goldman SA.

Clin Ther. 1998;20 Suppl C:C40-4. Review.

PMID:
9915089
10.

[Direct reporting by patients of adverse drug reactions in Spain].

Esther Salgueiro M, Jimeno FJ, Aguirre C, García M, Ordóñez L, Manso G.

Farm Hosp. 2013 Jan-Feb;37(1):65-71. doi: 10.7399/FH.2013.37.1.121. Review. Spanish.

11.

Prescription-event monitoring--recent progress and future horizons.

Mann RD.

Br J Clin Pharmacol. 1998 Sep;46(3):195-201. Review. No abstract available.

12.

[Incidence and prevalence of adverse drug reactions].

Haramburu F, Pouyanne P, Imbs JL, Blayac JP, Bégaud B.

Presse Med. 2000 Jan 22;29(2):111-4. Review. French.

PMID:
10682042
13.

Electronic toxicity monitoring and patient-reported outcomes.

Basch EM, Reeve BB, Mitchell SA, Clauser SB, Minasian L, Sit L, Chilukuri R, Baumgartner P, Rogak L, Blauel E, Abernethy AP, Bruner D.

Cancer J. 2011 Jul-Aug;17(4):231-4. doi: 10.1097/PPO.0b013e31822c28b3. Review.

14.

Community-based therapeutic drug monitoring. Useful development or unnecessary distraction?

Campbell M.

Clin Pharmacokinet. 1995 Apr;28(4):271-4. Review. No abstract available.

PMID:
7648756

Supplemental Content

Support Center